Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Follow-Up Questions
Acrivon Therapeutics Inc의 CEO는 누구입니까?
Dr. Peter Blume-Jensen은 2018부터 회사에 합류한 Acrivon Therapeutics Inc의 Chairman of the Board입니다.
ACRV 주식의 가격 성능은 어떻습니까?
ACRV의 현재 가격은 $1.66이며, 전 거래일에 decreased 0.53% 하였습니다.
Acrivon Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Acrivon Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Acrivon Therapeutics Inc의 시가총액은 얼마입니까?
Acrivon Therapeutics Inc의 현재 시가총액은 $52.2M입니다
Acrivon Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Acrivon Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 9명의 매수, 2명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
